A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

New England Journal of Medicine

Volumn 370, Issue 19, 2014, Pages 1809-1819

  Blom, Dirk J ^a   Hala, Tomas ^c   Bolognese, Michael ^e   Lillestol, Michael J ^f   Toth, Phillip D ^g   Burgess, Lesley ^b   Ceska, Richard ^d   Roth, Eli ^h   Koren, Michael J ^j   Ballantyne, Christie M ^k   Monsalvo, Maria Laura ^l   Tsirtsonis, Kate ^m   Kim, Jae B ^l   Scott, Rob ^l   Wasserman, Scott M ^l   Stein, Evan A ⁱ  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c Center for Clinical and Basic Research CCBR   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e Bethesda Health Research Center   (United States)

^f Lillestol Research LLC   (United States)

^g Midwest Institute for Clinical Research   (United States)

^h Sterling Research Group   (United States)

ⁱ Metabolic and Atherosclerosis Research Center   (United States)

^j Jacksonville Center for Clinical Research   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l AMGEN INC   (United States)

^m AMGEN LTD   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CREATINE KINASE; EVOLOCUMAB; EZETIMIBE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGY; ANEMIA; ANGINA PECTORIS; ARTHRALGIA; ARTHRITIS; ARTHROPOD DISEASE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHMA; ATHEROSCLEROSIS; BACKACHE; BRONCHITIS; CONSTIPATION; CONTROLLED STUDY; CONTUSION; COUGHING; CREATINE KINASE BLOOD LEVEL; CYSTITIS; DIARRHEA; DIET THERAPY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSPEPSIA; ECZEMA; FATIGUE; FEMALE; FEVER; FOOT FRACTURE; GASTRITIS; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOGENICITY; INFLUENZA; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSOMNIA; LACERATION; LIMB PAIN; LIPOPROTEIN BLOOD LEVEL; MALE; MIGRAINE; MULTICENTER STUDY; MUSCLE SPASM; MUSCLE STRAIN; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NECK PAIN; NEPHROLITHIASIS; NOSE OBSTRUCTION; OROPHARYNX PAIN; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; TENDINITIS; THORAX PAIN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ULTRACENTRIFUGATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO; VIRUS INFECTION; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; AZETIDINES; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PROPROTEIN CONVERTASES; PYRROLES; SERINE ENDOPEPTIDASES;

EID: 84899846576     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1316222     Document Type: Article

References (16)

1. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res 2012;53:2515-24.
2. Stein EA, Swergold GD. Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics. Curr Atheroscler Rep 2013;15:310.
3. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012;380:2007-17.
4. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012;380:1995-2006.
5. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012;126:2408-17.
6. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012;308:2497-506.
7. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-900.
8. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59:2344-53.
9. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012;380:29-36.
10. Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation against LDL-C (OSLER) randomized trial. Circulation 2014;129:234-43.
11. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
12. Lipid Research Clinics. Manual of laboratory operations: lipid and lipoprotein analysis (revised). Washington, DC: Government Printing Office, 1982. (DHHS publication no. (NIH) 75-67815.)
13. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med 1989;9:105-35. (Pubitemid 19070302)
14. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012;60:1888-98.
15. Stone NJ, Robinson JG, Lichtenstein AH, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 ACC/AHA Cholesterol Guideline. Ann Intern Med 2014 January 28 (Epub ahead of print).
16. Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein (a) with the PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of over 1300 patients in 4 phase 2 trials. J Am Coll Cardiol 2014 January 27 (Epub ahead of print).